Company / Current Liabilities
CytomX Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$46.6M
FY2025
5-year range
$46.6M / $155.9M
FY2021-FY2025
Trend
-45.7%
vs FY2024
Sector context
#146 of 213
Health Care
What the data says
At $47M, CytomX Therapeutics, Inc.'s current liabilities ranks #68 of 213 in the Health Care sector. Current Liabilities has fluctuated over the past 10 years, ranging from $36M in FY2016 to $156M in FY2023.
Based on SEC 10-K filings.
$47M in FY2025 with a 5-year CAGR of -14.3%.
Improved from $156M to $47M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -32.7%
- 5-Year CAGR
- -14.3%
- 10-Year CAGR
- -
Sector benchmark
#68 of 213 in Health CareTop 31% of 213This company $46.6M Sector average $1.6B
▼
-97.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -14.3%, indicating a declining trend.
- In FY2025, current liabilities decreased 45.7% year-over-year.
- Ranks #146 out of 213 companies in the Health Care sector.
- Peak current liabilities was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.6M | -45.7% |
| FY2024 | $85.8M | -45.0% |
| FY2023 | $155.9M | +2.2% |
| FY2022 | $152.6M | +43.5% |
| FY2021 | $106.3M | +5.3% |
| FY2020 | $100.9M | +17.9% |
| FY2019 | $85.6M | -12.6% |
| FY2018 | $97.9M | +60.1% |
| FY2017 | $61.1M | +71.0% |
| FY2016 | $35.8M | +127.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026